In this article, we are going to take a look at where Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...

Collegium Pharmaceutical (COLL) reported $181.95 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 21.5%. EPS of $1.77 for the same period compares ...

Analysts on Wall Street project that Collegium Pharmaceutical (COLL) will announce quarterly earnings of $1.54 per share in its forthcoming report, representing a decline of 2.5% year over year.

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for. Collegium Pharmaceutical beat analysts’ revenue ...

The Neubauer Collegium for Culture and Society has announced nine new projects for 2025-26. Each year Collegium projects bring together University faculty and other researchers to work through ...

The Collegium also recommended that Justice Manjusha Ajay Deshpande's term as an additional judge be renewed for a year. The Supreme Court Collegium has recommended that three additional judges of the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW DELHI: The Health Ministry has called the AIIMS Director for the review of the collegium system implemented in the institute last year. The Union Ministry had implemented this system to check ...

STOUGHTON, Mass. - Collegium Pharmaceutical , Inc. (NASDAQ:COLL), a diversified biopharmaceutical company with a market capitalization of nearly $1 billion and impressive gross profit margins of 87%, ...